XOMA Royalty Corporation Stock Price, News & Analysis

XOMA Corporation has secured a $0.5 million milestone payment from Janssen Biotech for the first patient dosed in a Phase 3 clinical trial of a biologic asset. This marks the second molecule to reach Phase 3 since XOMA shifted to a biotech royalty aggregator model in 2017. The company anticipates further milestone payments and royalties upon successful marketing approval and commercialization of the asset. With a portfolio of advancements, XOMA is positioned to potentially enhance shareholder value through its partnered programs.

XOMA Corporation (Nasdaq: XOMA) has expanded its portfolio of potential future milestone and royalty assets by adding three Affimed N.V. innate cell engager (ICE®) programs. The additions include AFM13 and AFM24, both designed to harness the innate immune system against cancer. XOMA is eligible for undisclosed payments on future sales and milestone payments upon marketing approvals of these molecules. CEO Jim Neal expressed excitement over the maturation of legacy technology agreements into potential revenue-generating assets, enhancing value for shareholders.

XOMA Corporation (Nasdaq: XOMA) announced the closing of its public offering of 1,600,000 depositary shares, representing a 1/1000th interest in its 8.375% Series B Cumulative Perpetual Preferred Stock. The offering raised gross proceeds of $40 million, netting approximately $38 million after fees. The funds will support a segregated dividend account and general corporate purposes, including future acquisitions related to drug development. Shares will trade on Nasdaq under the symbol 'XOMAO' soon.

XOMA Corporation has announced a public offering of 1,400,000 depositary shares at $25.00 each, raising $35.0 million in gross proceeds. Each share represents a 1/1000th interest in the company’s 8.375% Series B Cumulative Perpetual Preferred Stock. The offering, with a 30-day underwriter option for 200,000 additional shares, is set to close around April 9, 2021. Proceeds will fund a segregated dividend account and general corporate purposes, including future acquisitions related to drug development. Shares will trade under the symbol XOMAO.

XOMA Corporation has initiated an underwritten public offering of depositary shares, each representing a 1/1000^th fractional interest in its Series B Cumulative Perpetual Preferred Stock, priced at a liquidation preference of $25.00 per depositary share. The offering, led by several financial institutions, will use net proceeds primarily for funding acquisitions related to drug development programs. XOMA's offering is registered under an effective Form S-3 with the SEC, and additional shares may be available for purchase by underwriters.

Viracta Therapeutics (Nasdaq: VIRX) and XOMA Corporation (Nasdaq: XOMA) announced the acquisition of milestone and royalty rights for two clinical-stage drug candidates through a $13.5 million upfront payment. XOMA may pay up to $20 million in milestone payments. The candidates include DAY101, in a Phase 2 trial for pediatric glioma, and vosaroxin, aimed at treating acute myeloid leukemia. This deal is expected to provide Viracta with non-dilutive capital to support upcoming trials for Epstein-Barr virus-related cancers.

XOMA Corporation (Nasdaq: XOMA) announced a cash dividend of $0.71875 per share for its Series A Cumulative Perpetual Preferred Stock (XOMAP). The dividend will be paid on or about April 15, 2021, to shareholders on record as of the close of business on April 2, 2021. This reflects the company’s ongoing commitment to returning value to its shareholders.

XOMA has developed a diverse portfolio licensed to other biotech firms, focusing on milestone and royalty opportunities within drug development.

XOMA Corporation reported a recognized revenue of $29.4 million for 2020, a significant increase from $18.4 million in 2019. The company achieved a milestone earning of $25 million following Novartis' Phase 2 trial initiation of NIS793 for metastatic pancreatic cancer. XOMA also completed a $24.6 million Series A Preferred Stock offering, paying an 8.625% dividend. As of December 31, 2020, XOMA held $84.2 million in cash, marking a solid financial position to support future operations and projects.

On February 23, 2021, XOMA Corporation announced that CEO Jim Neal will present at two upcoming investor conferences. He will participate in a panel at the Cowen 41st Annual Virtual Health Care Conference on March 2, 2021, discussing clinical development. Additionally, XOMA will present at the H.C. Wainwright Global Life Sciences Conference, with on-demand access starting March 9, 2021. XOMA specializes in a portfolio of partnered programs and antibody therapeutics, aiming to generate milestone and royalty revenues for shareholders.